AMILI, a Singapore-based precision gut microbiome company, has raised $10.5 million in a Series A funding led by Vulcan Capital, the investment arm of the late Microsoft Corp co-founder Paul Allen.
Other new investors include Pruksa Group, TVM Capital Healthcare, Emtek Group, Capital Code, Pureland Group, Blue7 and SEEDS Capital, the investment arm of Enterprise Singapore.
GK Goh and other existing investors also participated in the round.
The funds raised will be used to accelerate microbiome research partnerships and discovery, develop AMILI PRIME and deepen AMILI’s presence in Southeast Asia initially and the rest of Asia subsequently.
